Prnewswireยท2025-07-24 12:00Core Viewpoint - Eli Lilly and Verve Therapeutics have completed a tender offer for Verve's common stock, with a purchase price of $10.50 per share and a contingent value right potentially worth up to $3.00 per share, which expired on July 23, 2025 [1][2]. Group 1: Acquisition Details - The tender offer resulted in 49,882,464 shares being validly tendered, representing approximately 55.7% of the outstanding shares [2]. - All conditions for the acquisition have been satisfied, and Lilly will proceed to pay for the validly tendered shares [2]. - The acquisition is expected to be finalized on July 25, 2025, in accordance with the definitive agreement [3]. Group 2: Company Profiles - Verve Therapeutics is a clinical-stage company focused on developing genetic medicines for cardiovascular diseases, with lead programs targeting key drivers of atherosclerosis [4]. - Lilly is a long-established pharmaceutical company dedicated to advancing healthcare solutions across various significant health challenges, including diabetes, obesity, Alzheimer's disease, and cancer [5].